Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 0.81 |
| ▸ | THRB | P10828 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12849250 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL2453645 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL30142606 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL12083012 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL22215232 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL150460 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| Carbamic Acid SCHEMBL2453716 | 0.92 | KDM4E (0.85) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL31663895 | 0.92 | KDM4E (0.85) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| Ether SCHEMBL7982613 | 0.91 | KDM4E (0.83) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL4104614 | 0.90 | KDM4E (0.81) | KDM4EMEN1KMT2ACYP2D6TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025134070-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | ARIBIO CO., LTD. (KR) | 2025-06-26 | — | — | WO | claimed |
| US-20250205239-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | ARIBIO CO LTD (KR) | 2025-06-26 | — | — | US | claimed |
| EP-4543454-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | Aribio Co., Ltd (KR) | 2025-04-30 | — | — | EP | claimed |
| WO-2025006982-A1 | POTENT AND SELECTIVE DOPAMINE D3 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-01-02 | — | — | WO | claimed |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-12 | — | — | US | claimed |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-24 | — | — | US | claimed |
| WO-2023248206-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | ARIBIO CO., LTD. (KR) | 2023-12-28 | — | — | WO | claimed |
| US-20230324359-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2023-10-12 | — | — | US | claimed |
| US-11458141-B2 | Aryl hydrocarbon receptor (AhR) agonists for the prevention and treatment of inflammatory disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-10-04 | — | — | US | claimed |
| US-20220265643-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-08-25 | — | — | US | claimed |
| EP-0575954-A1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-12-29 | — | — | EP | claimed |
| EP-0571434-A1 | A PROCESS FOR THE PREPARATION OF 1,3a,8-TRIMETHYL-1,2,3,3a,8,8a-HEXAHYDRO-PYRROLE 2,3-b]INDOL-5(3aS,8aR)-HEPTYLCARBAMATE. | LABORATORIO CHIMICO INT SPA (IT) | 1993-12-01 | — | — | EP | claimed |
| EP-0550007-A2 | Eseroline derivatives having anticholinesterase activity, a process for their preparation and pharmaceutical compositions containing them | AESCULAPIUS FARMACEUTICI S.r.l. (IT) | 1993-07-07 | — | — | EP | claimed |
| EP-0513703-A2 | Carbamate esters of eseroline having anticholinesterase activity, a process for their preparation and relative pharmaceutical compositions containing them as the active principle | MAGIS FARMACEUTICI S.p.A. (IT) | 1992-11-19 | — | — | EP | claimed |
| WO-1992014735-A1 | A PROCESS FOR THE PREPARATION OF 1,3a,8-TRIMETHYL-1,2,3,3a,8,8a-HEXAHYDRO-PYRROLE[2,3-b]INDOL-5(3aS,8aR)-HEPTYLCARBAMATE | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 1992-09-03 | — | — | WO | claimed |
| EP-0499179-A1 | A process for the preparation of 1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydro-pyrrole/2,3-b/indol-5(3aS,8aR)-heptylcarbamate | LABORATORIO CHIMICO INTERNAZIONALE S.p.A. (IT) | 1992-08-19 | — | — | EP | claimed |
| EP-0486958-A1 | Physostigmine derivatives | MEDIOLANUM FARMACEUTICI s.r.l. (IT) | 1992-05-27 | — | — | EP | claimed |
| US-4978673-A | ANTICHOLINERGIC AGENTS | MEDIOLANUM FARMACEUTICI S.R.L. CONSIGLIO NAZIONALE DELLE RICERCH (IT) | 1990-12-18 | — | — | US | claimed |
| US-4971992-A | Analgesics | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-11-20 | — | — | US | claimed |
| EP-0298202-A1 | Organic salts of physostigmine derivatives | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1989-01-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | OPRD1, OPRK1, DRD3 | KDM4E 3115/4885MEN1 4848/4885KMT2A 1226/4885 |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | DRD3, OPRD1, DRD2 | KDM4E 2788/4885MEN1 4866/4885KMT2A 1328/4885 |
| US-20220265643-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | OPRD1, OPRK1, DRD3 | KDM4E 3115/4885MEN1 4848/4885KMT2A 1226/4885 |
| US-11458141-B2 | Aryl hydrocarbon receptor (AhR) agonists for the prevention and treatment of inflammatory disorders | AHR, ARNT, MTNR1A | KDM4E 4392/4885MEN1 4880/4885KMT2A 3016/4885 |
| US-20230324359-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | GPX4, GPX1, ALOX15 | KDM4E 4267/4885MEN1 4562/4885KMT2A 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.